Loading
Mice carrying the same mutations as human cancers so that tumours arise in the right tissue with an intact immune system; the KPC pancreatic model is the best known.
Genetically engineered mouse models (GEMMs) use tissue-specific promoters and inducible systems to switch on oncogenes such as Kras and delete tumour suppressors such as Trp53 or Pten, so tumours develop in situ with a native stroma and immune system. The KPC pancreatic cancer model, Kras-driven lung models and Pten-null prostate models are used to study tumour evolution, immunotherapy and prevention, and CRISPR now speeds model creation. They are slow, expensive and less genetically diverse than human tumours.
Cre-lox or inducible recombination activates or deletes cancer genes in a chosen cell type, producing autochthonous tumours over weeks to months.
Query for this technology: (TITLE:"Genetically engineered mouse models" OR ABSTRACT:"Genetically engineered mouse models") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Genetically engineered mouse models, not a curated reading list.
Shares Patient-derived xenografts, Patient-derived organoids.
Shares Patient-derived xenografts, Patient-derived organoids.
Shares Patient-derived xenografts, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.
Shares Patient-derived xenografts, Patient-derived organoids, Prostate cancer.
Shares Patient-derived xenografts, Patient-derived organoids.
Shares Patient-derived xenografts, Patient-derived organoids.
Shares Patient-derived xenografts, Patient-derived organoids.
Shares Patient-derived xenografts, Pancreatic ductal adenocarcinoma.